Efficacy of probing with mitomycin-c in treatment of nasolacrimal duct obstruction.

Efficacy of probing accompanied by mitomycin-c for treatment of complete, primery nasolacrimal duct obstruction in adults in Jahrom Mottahari hospital between 1386-88

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013040310241N1

Enrollment

140

Registered

2013-04-11

Start date

2008-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasolacrimal duct obstruction.

Interventions

Intervention 1: 0.2 mg/ml mitomycin-c during nasolacrimal probing. Intervention 2: Normal saline during nasolacrimal probing.

Treatment - Drugs

Placebo

0.2 mg/ml mitomycin-c during nasolacrimal probing

Normal saline during nasolacrimal probing

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:1. Adults aged 18 or more. 2. Both sexes of men and women. 3. Patients with chief complaint of epiphora. Exclusion criteria: 1. Eye trauma. 2. Nasal structure abnormalities. 3. lacrimal system tumors.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Amount of epiphora. Timepoint: Two weeks, 1, 3, 6, and 9 months post intervention. Method of measurement: Observational.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Morteza Pourahmad

Jahrom University of Medical Sciences

mohammad_gh70@yahoo.com+98 79 1334 0406

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026